Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer

European Journal of Cancer

Volumn 49, Issue 11, 2013, Pages 2461-2468

  Gauler, Thomas Christoph ^a   Christoph, Daniel Christian ^a,b   Fischer, Juergen ^c   Frickhofen, Norbert ^d   Huber, Rudolf ^e   Gonschorek, Christine ^f   Roth, Katrin ^f   Giurescu, Marius ^f   Eberhardt, Wilfried Ernst Erich ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Center for Thoracic Surgery and Pneumology   (Germany)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f BAYER PHARMA AG   (Germany)

Author keywords

Chemotherapy; Cisplatin; Phase I; Sagopilone; Small cell lung cancer

Indexed keywords

CISPLATIN; SAGOPILONE;

ADULT; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; KIDNEY FAILURE; LUNG SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; PARESIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERTIGO; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOTHIAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; EPOTHILONES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; PROSPECTIVE STUDIES;

EID: 84879305197     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.03.029     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
2. F.A. Shepherd, J. Crowley, and P. Van Houtte The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer J Thorac Oncol 2 12 2007 1067 1077
3. J.P. Chute, T. Chen, and E. Feigal Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress J Clin Oncol 17 6 1999 1794 1801
4. I.K. Demedts, K.Y. Vermaelen, and J.P. van Meerbeeck Treatment of extensive stage small-cell lung carcinoma: current status and future prospects Eur Respir J 35 2010 202 215
5. K. Noda, Y. Nishiwaki, and M. Kawahara Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2 2002 85 91
6. J. Jiang, X. Liang, and X. Zhou A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer J Thorac Oncol 5 6 2010 867 873
7. S. Onoda, N. Masuda, and T. Seto Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 24 34 2006 5448 5453
8. D.S. Ettinger, R. Jotte, and P. Lorigan Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 28 15 2010 2598 2603
9. S. Goodin, M.P. Kane, and E.H. Rubin Epothilones: mechanism of action and biologic activity J Clin Oncol 22 10 2004 2015 2025
10. G. Ferrandina, M. Mariani, and M. Andreoli Novel drugs targeting microtubules: the role of epothilones Curr Pharm Des 18 2012 2793 2803
11. G. Rustin, N. Reed, and G.C. Jason A phase-II trial two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer Ann Oncol 22 2011 2411 2416
12. S. McMeekin, R. Patel, and C. Verschraegen Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer Br J Cancer 106 2012 70 76
13. R.C. DeConti, A.P. Algazi, and S. Andrews Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma Br J Cancer 103 10 2010 1548 1553
14. R. Stupp, A. Tonsoni, and W. Taal Phase-II trial of the epothilone analog sagopilone (ZK-EPO) in patients with recurrent glioblastoma: initial reports of the EORTC study 25061 J Clin Oncol 2008 26 [May 20 suppl.; abstr. 2015]
15. U. Gatzemeier, J. von Pawel, and C. Eschbach Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non small cell lung cancer Eur J Cancer 2007 53786568 [abstract]
16. M.J. Edelman, and M. Shvartsbeyn Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance Clin Lung Cancer 13 3 2012 171 180
17. J. Hoffmann, I. Fichtner, and M. Lemm Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases Neuro Oncol 11 2 2009 158 166
18. M.G. Kris, P.J. Hesketh, and M.R. Somerfield American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006 J Clin Oncol 24 18 2006 2932 2947
19. P. Schmid, P. Kiewe, and K. Possinger Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors Ann Oncol 21 3 2010 633 639
20. D. Arnold, W. Voigt, and P. Kiewe Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial Br J Cancer 101 8 2009 1241 1247
21. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
22. M. Edelman, C. Schneider, and C. Tsai Randomized trial of ixabepilone plus carboplatin or paclitaxel plus carboplatin in ß3 Tubulin overexpressing non-small-cell lung cancer J Thorac Oncol 5 2010 12 [suppl. December S508; abstr. 20]
23. L.B. Michaud The epothilones: how pharmacology relates to clinical utility Ann Pharmacother 43 7 2009 1294 1309
24. Z. Ghoreishi, A. Esfahani, and A. Djazayeri Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial BMC Cancer 12 2012 355 362
25. C. Lhomme, D. Berton-Rigaud, and F. Joly Results from a randomized phase-II study to evaluate the safety and efficacy of acetyl-l-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON) J Clin Oncol 2011 29 [suppl.; abstr. 9116]
26. E.H. Rubin, J. Rothermel, and F. Tesfaye Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors J Clin Oncol 23 36 2005 9120 9129
27. M. Forster, S. Kaye, and A. Oza A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer Clin Cancer Res 13 14 2007 4178 4184
28. S. Mozzetti, R. Iantomasi, and I. De Maria Molecular mechanisms of patupilone resistance Cancer Res 68 24 2008 10197 10204
29. L. Yee, T. Lynch, and M. Villalona-Calero A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small-cell lung cancer J Clin Oncol 2005 23 [June 1 suppl.; abstr. 7127]